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1492shown by an increased risk of acute cardiovascular
and cerebrovascular events in the early phase of the
disease (2). We have recently shown a signiﬁcant as-
sociation between platelet activation in vivo and
myocardial infarction (MI), suggesting a role for
platelets as a trigger of myocardial ischemia (1). We
also noted that community-acquired pneumonia
(CAP) patients on treatment with aspirin had not
complete inhibition of platelet thromboxane (Tx) A2,
which could denote an incomplete ability of aspirin to
fully inhibit COX1 (1). Drs. Savas and Kalay raise the
possibility that such incomplete inhibition may
depend on concomitant use of nonsteroidal anti-
inﬂammatory drugs (NSAIDs); however, none of our
CAP patients took NSAIDs during the hospital stay,
and in case of need, paracetamol was used. Another
pharmacological mechanism potentially accounting
for the incomplete inhibition of platelet TxA2 is
related to the aspirin formulation, which was enteric-
coated in 95% of our aspirin-treated patients. Thus, a
previous study demonstrated that enteric-coated
aspirin may be associated with impaired COX1 inhi-
bition, likely because a variable absorption of aspirin
in the gastrointestinal tube (3). The authors also
requested more information on MI diagnosis because
the troponin increase could be related to concomitant
renal disease, and electrocardiographic changes may
not be speciﬁc for MI diagnosis. Although we agree
that renal disease could affect serum troponin levels
of our population (4), an increase of troponin alone,
which was monitored every 12 h from hospitalization,
was insufﬁcient for MI diagnosis; thus, we followed
the universal MI deﬁnition, which requires the coex-
istence of a troponin increase with characteristic ST-
segment changes.*Francesco Violi, MD
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Platelet Activation and
PneumoniaIs Soluble P-Selectin the Right Marker?We read with interest the paper by Cangemi et al. (1)
reporting a signiﬁcant association between platelet
activation and myocardial infarction (MI) that was
based on the observation of higher levels of plasma
soluble (s)CD-40L and sp-selectin and serum throm-
boxane (Tx) B2 in patients who were hospitalized for
pneumonia and who had development of MI. About
20 years ago, there was tremendous interest in the
potential utility of p-selectin as a diagnostic marker of
early acute coronary syndromes and as a target for
pharmacological inhibition. However, at the present
time, the utility of sp-selectin as a reliable marker of
platelet activation to identify MI is still a matter of
debate. About 17 years ago, we reported the relation
of sp-selectin with acute MI (AMI) (2). In our pilot
study, sp-selectin levels were determined in identical
samples by 2 different enzyme-linked immunosor-
bent assays at pre-speciﬁed time points in 23 patients
with AMI enrolled in the GUSTO-III (Global Utilization
of Streptokinase and Tissue Plasminogen Activator
for Occluded Coronary Arteries) trial and were
compared with healthy control subjects. Plasma
concentrations of sp-selectin were consistently at
least twice higher in patients with AMI when
measured by use of both assays. We also showed that
sp-selectin rose early after reperfusion, a factor that
may have inﬂuenced the detection of elevated
sp-selectin in the Cangemi study, because only
2 sp-selectin measurements were made in the
latter study. To evaluate the diagnostic utility of
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1493sp-selectin and membrane-bound p-selectin, a sub-
sequent single-center study (n ¼ 136) was conducted
by our group (3). We showed that the p-selectin pro-
ﬁle alone did not reliably differentiate acute coronary
syndromes from noncardiac chest pain due to inter-
individual variability and low overall sensitivity;
many patients with noncardiac chest pain had high
soluble and membrane-bound p-selectin. Finally, in a
multicenter study (n ¼ 338) in patients presenting
with chest pain, it was shown that membrane bound
p-selectin expression, an established marker of
platelet activation, was unrelated to the level of
sp-selectin, irrespective of the etiology of chest pain.
Taken together, all of these results strongly suggest
that sp-selectin cannot reliably serve as a surrogate
marker to indicate platelet activation in patients
with AMI and noncardiac chest pain (4). Regarding
CD-40L, despite the earlier enthusiasm about the
potential of this marker as a diagnostic tool, there
have been no reports that this marker has clinical
importance. Its lack of utility may be related
to artifacts associated with its measurement.
Finally, in addition to platelets, endothelial cells and
monocytes/macrophages express cyclooxygenase-2.
In states of intense inﬂammation, such as pneu-
monia, in which cyclooxygenase-2 expression is high,
elevated total serum TxB2 levels may be the result of
increased TxA2 synthesis in leukocytes or caused
by transcellular synthesis of TxA2 in platelets (5).
Therefore, we suggest that the results of the current
study must be interpreted with caution for 3 reasons:
1) the assessment of platelet activation by the pro-
posed soluble markers; 2) the elevation of sp-selectin
and TxB2 in noncardiac disease states; and 3) the prior
evidence that both soluble and membrane-bound
p-selectin are not robustly associated with proven MI.*Paul A. Gurbel, MD
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REPLY: Platelet Activation and PneumoniaIs Soluble P-Selectin the Right Marker?We thank Dr. Gurbel and colleagues for their inter-
esting comments related to our recent report showing
an association between enhanced in vivo platelet
activation and myocardial infarction in patients with
community-acquired pneumonia (CAP) (1).
The authors raise relevant questions as to whether
in vivo platelet activation occurs in patients with
pneumonia and is robustly associated with myocar-
dial infarction. The authors question in particular
the assay validity of soluble-p-selectin (sp-selectin)
and soluble CD-40L (sCD-40L) as markers of in vivo
platelet activation because in vitro artifacts or extra-
platelet sources of sp-selectin or sCD-40L render
the biological interpretation to be difﬁcult. We agree
with Dr. Gurbel and colleagues that platelets are not
the only cells activated during infections because
leukocytes may also be stimulated and potentially
contribute to thromboxane B2 over-production.
Regarding the assay validity of sp-selectin and
sCD-40L as markers of platelet activation, data are
controversial as demonstrated, for example, by an
interventional study suggesting that sCD-40L is
partly of platelet origin because it is signiﬁcantly
reduced by aspirin treatment (2). We also agree with
the authors that the increase of plasma levels of
sp-selectin and sCD-40L are not speciﬁc for acute
coronary syndrome because they may be elevated
also in patients with stable atherosclerosis or
atherosclerotic risk factors (2). Of note, with the use
of these variables as biomarkers of platelet activation,
prospective studies in patients with stable athero-
sclerosis or acute coronary syndromes demonstrated
that either sCD-40L or sp-selectin predicts poor car-
diovascular events (2).
However, regarding our report on CAP, the associ-
ation between biomarkers of platelet activation with
